| Date | Title | | | December 23, 2014 | Incyte to Present at the 33rd Annual J. P. Morgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 23, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
33rd Annual J. P. Morgan Healthcare Conference on Monday,
January 12th at 8:30 a.m. (PST) / 11:30 a.m. (EST) in San
Francisco.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available. Investors interested i... |
|  | | December 09, 2014 | Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis| FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS
INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. The study included patients with moderately-to-severely active rheumatoid arthritis (RA) who previously failed one or more tumor necrosis... |
| | | December 04, 2014 | FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera| The first and only FDA-approved treatment for patients with
polycythemia vera (PV) who have had an inadequate response to or are
intolerant of hydroxyurea
PV is a rare blood cancer associated with overproduction of blood
cells that can cause serious cardiovascular complications, such as
stroke and heart attack1
Jakafi is the only treatment for patients with PV shown to provide
consistent hematocrit con... |
| | | December 02, 2014 | Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)| New analyses of the RESPONSE trial provide additional insights into
the efficacy of ruxolitinib in patients with polycythemia vera (PV)
who have had an inadequate response to or are intolerant of hydroxyurea
Data from the COMFORT, JUMP, and EXPAND trials reinforce the
efficacy and safety of ruxolitinib in patients with myelofibrosis (MF)
Data from trials of the combination of ruxolitinib and other
targeted agen... |
| | | November 17, 2014 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 17, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of December:
Piper Jaffray 26th Annual Healthcare Conference on Tuesday,
December 2, 2014 at 12:00 pm (EST) in New York; and
Oppenheimer 25th Annual Healthcare Conference on Thursday,
December 11, 2014 at 10:20 am (EST) in New York
... |
| | | October 30, 2014 | Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs| $97.8 million of 2014 third-quarter net product revenues from Jakafi®
(ruxolitinib), representing 63 percent growth over the same period
last year
2014 guidance for Jakafi net product revenues increased to range of
$350 million to $360 million, driven by continued strong growth in
underlying demand
Two milestone payments from Novartis earned in the third quarter,
totaling $85 million
... |
| | | October 23, 2014 | Incyte to Present at the Nomura BioPharma Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 23, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Nomura BioPharma Conference on Thursday, November 6, 2014 at 1:15 p.m.
(EST) in Boston.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available. Investors interested in listening to the
live webcast should ... |
| | | October 17, 2014 | Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 17, 2014--
Incyte Corporation (NASDAQ: INCY) today announced the appointment of
David Gryska as Executive Vice President and Chief Financial Officer,
effective October 31, 2014. Mr. Gryska will report to Hervé Hoppenot,
President and Chief Executive Officer.
Mr. Gryska will succeed David Hastings, who has served as Incyte’s
Executive Vice President and Chief Financial Officer since October 2003.
Mr. ... |
| | | October 15, 2014 | Incyte to Report Third Quarter 2014 Financial Results on October 30| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 15, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its third quarter 2014 financial results conference call for 8:30 a.m.
ET on Thursday, October 30, 2014. The schedule for the press release and
conference call is as follows:
... |
| | | October 02, 2014 | Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxolitinib) in Europe| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 2, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has earned a
$60 million milestone payment from Novartis related to reimbursement of
Jakavi® (ruxolitinib) in Europe. Incyte will record this
amount as contract revenue in the third quarter, and expects to receive
payment of $60 million in the fourth quarter.
Under the Incyte-Novartis Collaboration and License Agreement signed in
200... |
| | | September 08, 2014 | Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called Myeloproliferative Neoplasms (MPNs) and Honor MPN Heroes| Initiatives focus on increasing MPN Awareness
Multiple patient education events scheduled throughout September
Call for nominations – MPN Heroes™ recognition program
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2014--
September is Blood Cancer Awareness Month, and the MPN Coalition, a
group of seven patient organizations, has designated September 11, 2014,
as MPN Awareness Day. This day recognizes the approxi... |
| | | September 08, 2014 | Incyte to Present at the 21st Annual BioCentury NewsMakers Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
21st Annual BioCentury NewsMakers Conference on Friday,
September 26, 2014 at 2:00 p.m. (EDT) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available. Investors interested in listening to the
li... |
| | | August 05, 2014 | FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 5, 2014--
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and
Drug Administration (FDA) has accepted for filing the supplemental New
Drug Application (sNDA) for ruxolitinib as a potential treatment of
patients with polycythemia vera (PV) who have had an inadequate response
to or are intolerant of hydroxyurea. The sNDA includes results from the
RESPONSE Phase III trial, which were recently presen... |
| | | July 31, 2014 | Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs| $84.0 million of 2014 second-quarter net product revenues from
Jakafi® (ruxolitinib), representing 55
percent growth over the same period last year
2014 guidance for Jakafi net product revenues increased to range of
$330 million to $340 million, driven by strong underlying demand
Timely initiation of key pipeline programs, including initiation of
two pivotal trials of ruxolitinib in pancreatic cancer and three ... |
| | | July 30, 2014 | Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies| Incyte’s investigational oral IDO1 inhibitor INCB24360 to be evaluated
with Genentech’s investigational PD-L1 immune checkpoint inhibitor
MPDL3280A
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 30, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has entered
into a clinical trial agreement with Genentech to evaluate the safety,
tolerability and preliminary efficacy of Incyte’s oral indoleamine
dioxygenase-1 (IDO1) inhibit... |
| | | July 28, 2014 | Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information| Jakafi is the first and only FDA-approved treatment for patients with
intermediate or high-risk myelofibrosis
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 28, 2014--
Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food &
Drug Administration (FDA) has approved supplemental labeling for Jakafi®
(ruxolitinib) to include new Kaplan-Meier overall survival curves as
well as additional safety and dosing information. The new overall
surv... |
| | | July 23, 2014 | Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera| Statistical significance not achieved for the primary endpoint of
symptom control; positive trends in favor of ruxolitinib versus
hydroxyurea observed
RELIEF trial conducted in patients who were generally
well-controlled on hydroxyurea but reporting continued disease-related
symptoms, a different population than the pivotal Phase III RESPONSE
trial
RELIEF not included in, nor required for, polycythemia... |
| | | July 14, 2014 | Incyte to Report Second Quarter 2014 Financial Results on July 31| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its second quarter 2014 financial results conference call for 8:30 a.m.
ET on Thursday, July 31, 2014. The schedule for the press release and
conference call is as follows:
Q2 2014 Press Release: July 31, 2014 at 7:00 a.m. ET
Q2 2014 Conference Call: July 31, 2014 at 8:30 a.m. ET
... |
| | | July 08, 2014 | Incyte Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in Japan| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 8, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has earned a
$25 million milestone payment from Novartis in connection with the
approval of Jakavi® (ruxolitinib) in Japan for the treatment
of patients with myelofibrosis. Incyte will record this amount as
contract revenue in the third quarter. Under the Incyte-Novartis
Collaboration and License Agreement, Novartis received exclusive
develo... |
| | | June 12, 2014 | Incyte to Present at the 9th Annual JMP Securities Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 12, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the 9th
Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014
at 11:00 a.m. (EDT) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available. Investors interested in listening to the
... |
| | | June 03, 2014 | Pivotal Phase III Data in Polycythemia Vera Show that Jakafi® (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies| The trial met the primary composite endpoint of hematocrit control
and at least a 35 percent reduction in spleen volume
77 percent of patients treated with ruxolitinib versus 20 percent
on best available therapy achieved one or both of the components of
the primary endpoint
Approximately half of patients in the ruxolitinib group had at
least a 50 percent improvement in symptom score, compared with 5
pe... |
| | | June 02, 2014 | Incyte Announces Preliminary Results of a Phase I/II Study of Combination Immunotherapy in Patients with Melanoma| Clinical data suggest anti-tumor synergy between Incyte’s IDO1
inhibitor INCB24360 and ipilimumab described in an ASCO poster
highlights session
Among immunotherapy-naïve patients receiving INCB24360 combined
with ipilimumab, 42 percent had an objective response and 75 percent
achieved disease control
IDO1 inhibitor-based combination therapy represents a promising and
potentially synergistic approach t... |
| | | June 02, 2014 | Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi® (ruxolitinib) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer| Overall survival favored ruxolitinib plus capecitabine versus
capecitabine alone in pre-specified subgroup of patients with elevated
CRP, an established marker of systemic inflammation and poor prognosis
in cancer
These data support targeting onco-inflammation through the JAK-STAT
pathway and form the basis of an expanded clinical development program
evaluating ruxolitinib in pancreatic cancer and other solid tumor types
... |
| | | May 28, 2014 | New Data for Multiple Incyte Cancer Programs to Be Presented at the 2014 American Society of Clinical Oncology (ASCO) Meeting| Results from RECAP, a Phase II trial of ruxolitinib in metastatic
pancreatic cancer and proof-of-concept for the role of a JAK1/JAK2
inhibitor in treating onco-inflammation
Preliminary results from an ongoing Phase I/II trial of INCB24360, a
novel immuno-oncology compound, in combination with ipilimumab in
metastatic melanoma
Results from RESPONSE, a pivotal Phase III trial of ruxolitinib in
uncontroll... |
| | | May 27, 2014 | Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies| Phase I/II study to evaluate nivolumab, Bristol-Myers Squibb’s
investigational PD-1 immune checkpoint inhibitor with Incyte’s
investigational oral IDO1 inhibitor for multiple cancers
NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)--May 27, 2014--
Bristol-Myers
Squibb Company (NYSE: BMY) and Incyte
Corporation (Nasdaq: INCY) announced today the establishment of a
clinical trial collaboration to evaluate the safety, tolerability and
prel... |
| | | May 20, 2014 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--May 20, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of June:
Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014
at 10:30 am (EDT) in New York;
Goldman Sachs 35th Annual Global Healthcare Conference on
Tuesday, June 10, 2014 at 10:40 am (PDT) / 1:40 pm (EDT) in Rancho
Palo... |
| | | May 14, 2014 | Incyte and MedImmune Announce Collaboration on Immuno-Oncology Combination Clinical Trial| WILMINGTON, Del.--(BUSINESS WIRE)--May 14, 2014--
Incyte Corporation (Nasdaq: INCY) and MedImmune, the global biologics
research and development arm of AstraZeneca, announced today that they
have entered into a clinical study collaboration. The Phase I/II
oncology study will evaluate the efficacy and safety of MedImmune’s
investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in
combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1)
... |
| | | May 02, 2014 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--May 2, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of May:
Bank of America Merrill Lynch Health Care Conference on Tuesday, May
13, 2014 at 11:20 am (PDT) in Las Vegas; and
UBS Global Healthcare Conference on Monday, May 19, 2014 at 10:30 am
(EDT) in New York
The presentations... |
| | | May 01, 2014 | Incyte Reports 2014 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs| $69.7 million of 2014 first-quarter net product revenues from Jakafi®
(ruxolitinib); 6 percent increase in underlying demand over
fourth-quarter 2013
Positive top-line results from Phase III study of ruxolitinib in
patients with polycythemia vera keep sNDA filing on track for second
quarter 2014
Abstracts for ruxolitinib in pancreatic cancer and polycythemia vera
and for IDO1 inhibitor INCB24360 in mel... |
| | | April 16, 2014 | Incyte to Report First Quarter 2014 Financial Results on May 1| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 16, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its first quarter 2014 financial results conference call for 8:30 a.m.
ET on Thursday, May 1, 2014. The schedules for the press release and
conference call are as follows:
... |
| | | March 07, 2014 | Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera| Study of ruxolitinib versus best available therapy for patients
with polycythemia vera who are resistant to or intolerant of
hydroxyurea met primary endpoint
Ruxolitinib is the first selective JAK1/JAK2 inhibitor to
demonstrate efficacy in a Phase III trial for treating polycythemia
vera
Data expected to be presented at an upcoming scientific meeting
Supplemental new drug application pl... |
| | | February 18, 2014 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 18, 2014--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of March:
Cowen and Company 34th Annual Health Care Conference on
Monday, March 3, 2014 at 2:10 pm (EST) in Boston; and
Barclays Capital Global Healthcare Conference on Tuesday, March 11,
2014 at 11:15 am (EST) in Miami
The ... |
| | | February 12, 2014 | Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs| $72.9 million of fourth-quarter and $235.4 million of full-year
2013 net product revenues from Jakafi® (ruxolitinib)
Net product revenue guidance for 2014 in the range of $315 million
to $335 million, reflecting continued growth in underlying demand
Special Protocol Assessment obtained for Phase III clinical trial
of ruxolitinib in advanced or metastatic pancreatic cancer
Conference Call Scheduled... |
| | | February 05, 2014 | Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies| Phase I/II study to evaluate the safety and efficacy of Incyte’s
investigational oral IDO1 inhibitor with Merck’s investigational
anti-PD-1 immunotherapy for metastatic cancers
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 5, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has entered
into a clinical trial collaboration agreement with Merck, through a
Merck subsidiary, to evaluate the safety and efficacy of Incyte’s oral
indoleamine... |
| | | January 27, 2014 | Incyte to Report Fourth Quarter/Year-End 2013 Financial Results on February 12| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2014--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter/year-end 2013 financial results conference call for
8:30 a.m. ET on Wednesday, February 12, 2014. The schedules for the
press release and conference call are as follows:
... |
| | | January 14, 2014 | Incyte Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 14, 2014--
Incyte Corporation (Nasdaq: INCY) today announced that in connection
with the hiring, announced on January 13, 2014, of Hervé Hoppenot as
President and Chief Executive Officer, Mr. Hoppenot received an award of
restricted stock units (RSUs) to acquire 400,000 shares of Incyte common
stock. The RSUs will vest in equal annual increments over a six year
period, with the first installment vesting on December... |
| | | January 13, 2014 | Incyte Names Hervé Hoppenot President and Chief Executive Officer| Former President of Novartis Oncology to Lead Incyte’s Future Growth
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 13, 2014-- Incyte Corporation (Nasdaq:INCY) announced today that Hervé Hoppenot, former President of Novartis Oncology, has been named President and Chief Executive Officer of Incyte, effective immediately. Mr. Hoppenot, who also will join the Incyte Board of Directors, succeeds Paul A. Friedman, M.D. Dr. Friedman is retiring and will continue to serve on the Board.
“Hervé’s broad int... |
| |
|
